ORIGINAL ARTICLE

Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume

M Berk^{1,2,3,4,5,6}, O Dandash^{7,8}, R Daglas^{2,3,10}, SM Cotton^{2,3}, K Allott^{2,3}, A Fornito⁷, C Suo⁷, P Klauser^{7,8}, B Liberg^{8,9}, L Henry^{2,3}, C Macneil⁴, M Hasty⁴, P McGorry^{2,3}, Cs Pantelis^{6,8,10} and M Yücel^{7,10}

Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of first-episode mania (FEM) patients ($n = 26$) to longitudinally compare the putative protective effects of lithium and quetiapine on grey and white matter volume. A healthy control sample was also collected ($n = 20$). Using structural MRI scans, voxel-wise grey and white matter volumes at baseline and changes over time in response to treatment were investigated. Patients were assessed at three time points (baseline, 3 and 12-month follow-up), whereas healthy controls were assessed at two time points (baseline and 12-month follow-up). Patients were randomized to lithium (serum level 0.6 mmol l^{-1} , $n = 20$) or quetiapine (flexibly dosed up to 800 mg per day, $n = 19$) monotherapy. At baseline, compared with healthy control subjects, patients with FEM showed reduced grey matter in the orbitofrontal cortex, anterior cingulate, inferior frontal gyrus and cerebellum. In addition, patients had reduced internal capsule white matter volume bilaterally ($t_{1,66} > 3.20$, $P < 0.01$). Longitudinally, there was a significant treatment $\times$ time effect only in the white matter of the left internal capsule ($F_{2,112} = 8.54$, $P < 0.01$). *Post hoc* testing showed that, compared with baseline, lithium was more effective than quetiapine in slowing the progression of white matter volume reduction after 12 months ($t_{1,24} = 3.76$, $P < 0.01$). Our data support the role of lithium but not quetiapine therapy in limiting white matter reduction early in the illness course after FEM.

Translational Psychiatry (2017) 7, e1011; doi:10.1038/tp.2016.281; published online 24 January 2017

INTRODUCTION

Many people with bipolar disorder (BD) manifest a progressive course. This observation has been repeatedly verified^{1,2} and is manifested by progressively shorter inter-episode intervals, increasing rates of functional impairment, comorbidity, suicide, hospitalisation and reduced treatment responsiveness.^{3–8} Moreover, there are replicated reports of changes over time in brain volume, suggesting that these neuroanatomical alterations might be more pronounced with repeated episodes. A larger number of episodes have been associated with decreased cortical and subcortical structures including prefrontal and temporal cortices, the hippocampus and the striatum^{9–12} accompanied with an increase in lateral ventricular volume.^{13–15}

The timing of these serial changes in clinical and imaging variables remains uncertain. What is probable is that people at risk who later go on to develop BD do not, on aggregate, demonstrate marked deficits. These appear with the onset of the disorder, and are evident in an established disease.¹⁶ Similarly, structural changes are inconsistent at a first episode, with some studies

showing that individuals at a first episode manifest volumetric findings similar to controls,^{17,18} whereas other studies suggest that changes are already evident.¹⁹ Either way, the first episode appears to be the soonest pragmatic point to commence therapeutic strategies with neuroprotective potential.

A considerable body of evidence from non-randomized studies suggests that lithium may be associated with preservation or increase in cortical grey matter^{20,21} including the prefrontal cortex,²² amygdala and hippocampus.²³ Evidence supporting a protective role for antipsychotics such as quetiapine largely draws on the rather uncertain schizophrenia literature. While some evidence points to a protective role for quetiapine that ceases after abstinence,²⁴ other studies show either an increase only with typical antipsychotics,²⁵ mixed findings of volumetric increases and reductions²⁶ or dose-dependent effects.²⁷ A naturalistic study that examined longitudinal changes in grey and white matter in a cohort of schizophrenia and BD patients, treated with second-generation antipsychotics including quetiapine, found a significant reduction in the frontal cortex in the schizophrenia group and no change in the BD group.¹⁷

¹IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia; ²Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia; ³Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia; ⁴Orygen Youth Health Clinical Program, Parkville, VIC, Australia; ⁵Barwon Health and the Geelong Clinic, Swanston Centre, Geelong, VIC, Australia; ⁶Florey Institute for Neuroscience and Mental Health, Kenneth Myer Building, Royal Parade, Parkville, VIC, Australia; ⁷Brain and Mental Health Laboratory, School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, Australia; ⁸Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Carlton South, VIC, Australia and ⁹Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology (CLINTEC), and Division of Psychiatry, Karolinska Institutet, Stockholm, Sweden. Correspondence: Professor M Berk, School of Medicine, IMPACT Strategic Research Centre, Deakin University, Ryrie Street, PO Box 281, Geelong, VIC 3220, Australia. E-mail: mikebe@barwonhealth.org.au

¹⁰These authors contributed equally to this work.

The study was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12607000639426; <http://www.anzctr.org.au>).

Received 4 July 2016; revised 13 November 2016; accepted 27 November 2016

Despite the considerable evidence that atypical agents have clinical utility in BD, there is a lack of randomised controlled trials with imaging endpoints focusing on volumetric changes in response to treatment. To examine which agent may have better neuroprotective properties, a cohort of individuals were studied who had been stabilized after a first episode of mania on a combination of lithium and quetiapine and then randomized to either lithium or quetiapine monotherapy. Voxel-based morphometry was utilised to determine white and grey matter volume changes at baseline and at 3 and 12 months in treatment groups in comparison with healthy controls. We hypothesised that first-episode mania (FEM) patients would show altered brain volume compared with control subjects at baseline and that lithium and quetiapine treatments would be equivalent in affecting changes in brain volume in the first year following a first episode of mania.

MATERIALS AND METHODS

Study design

A single-blind controlled randomised parallel group design was conducted over 52 weeks at two sites in Melbourne, Australia; Orygen, The National Centre of Excellence in Youth Mental Health, the Early in Life Mental Health Service and the Recovery and Prevention of Psychosis services at Monash Health. In this trial, all individuals presenting with an acute first episode of mania with psychotic features were stabilised on a combination of quetiapine plus lithium in an open manner as part of a routine care protocol. Following the provision of informed consent, patients were randomised after remission (a period of between 2 and 3 months) to either lithium or quetiapine monotherapy. The study was conducted according to the Good Clinical Practice guidelines and was approved by all relevant ethical committees.

Participants

Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for a manic episode on the Structured Clinical Interview for DSM-IV-TR—Patient Edition (SCID-I/P)²⁸ were recruited between December 2008 through December 2013. Individuals with a first-episode illness of bipolar I disorder, substance-induced mood disorder or schizoaffective disorder and aged 15–25 years were included. Other inclusion criteria included: a Young Mania Rating Scale (YMRS) score of at least 20 for the acute phase of a first episode of mania; no previously treated manic episode(s); capacity to provide informed consent to the study and comply with study procedures; be utilising effective contraception if female and to have been on quetiapine and lithium as standard therapy for at least 1 month before randomisation.

Exclusion criteria from the trial included: patients with a known or suspected clinically relevant systemic medical disorder; pregnant or lactating females; patients who had a prior sensitivity or allergy to quetiapine, lithium or their components; inability to comply with either the requirements of informed consent or the treatment protocol; non-fluency in English; history of epilepsy; clinically relevant biochemical or haematological abnormalities at baseline; patients at immediate risk of self-harm or risk to others; organic mental disease, including mental retardation (full-scale intelligence quotient < 70); and an absolute neutrophil count of $\leq 1.5 \times 10^9 \text{ l}^{-1}$. Use of cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment was not permitted including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir. Similarly, the use of cytochrome P450 inducers was not permitted in the 14 days preceding enrolment including phenytoin, carbamazepine, barbiturates, rifampicin, St John's Wort or glucocorticoids. Extra exclusion criteria applied to individuals with diabetes mellitus (DM): unstable DM defined as enrolment glycosylated haemoglobin (HbA1c) > 8.5; admission to hospital for treatment of DM or DM-related illness in the previous 12 weeks; not under physician care for DM; physician responsible for patient's DM care did not indicate that patient's DM was controlled; physician responsible for patient's DM care did not approve patient's participation in the study; had not been on the same dose of oral hypoglycaemic drug(s) for the 4 weeks before randomisation (8 weeks for thiazolidinediones); and daily insulin had been more than 10% outside their mean monthly dose on one or more occasions in the preceding 4 weeks.

All individuals presenting with an acute first manic episode with psychotic features were acutely stabilised on a combination of quetiapine plus lithium in an open manner as part of a routine care protocol. Individuals received quetiapine at a dose determined by the treating clinician. Optimal serum lithium levels targeted in the acute phase were between 0.8 and 1.0 mmol l⁻¹. Following clinical stabilisation (based on the global impression of the treating clinician or team), subjects were randomised to either quetiapine or lithium. Lithium levels of 0.6–0.8 mmol l⁻¹ were targeted in the maintenance phase, and the quetiapine dose was determined by the treating clinician (up to 800 mg per day).

Randomisation and blinding

At the discretion of the treating team, an independent statistician generated a computerised randomisation sequence 2–3 months following stabilisation from a FEM. A randomisation log was established and a set of sequentially ordered envelopes was kept in a locked filing cabinet at the Orygen Research Centre site. Care was taken to maintain the single-blind nature of the study; patients and clinical staff including treating psychiatrist and case managers knew which treatment the patient was receiving while research staff including research assistants, neuropsychologists and all individuals involved in neuroimaging, analysis and data management remained blinded to this information. Participants were instructed not to communicate information regarding treatment to the research assistants and imaging personnel by the study clinicians, and no information regarding treatment was communicated at team meetings or was included in the study files to which the research assistants had access.

Procedure

Clinical assessments were carried out at baseline and on fortnightly intervals for the first month, then on a monthly basis for the following two months and then at three monthly intervals thereafter concluding at the 12-month time point. The clinical assessment included observer-based ratings using the YMRS for manic symptoms, the Montgomery-Åsberg Depression Rating Scale²⁹ for depressive symptoms; the Brief Psychiatric Rating Scale³⁰ for overall psychopathology and severity of psychotic symptoms; and the Clinical Global Impression scale for use in BD³¹ to determine overall symptom severity. Control subjects underwent MRI scanning at baseline and at the 12-month time points, whereas FEM patients were scanned at baseline, 3 and 12-month time points to better assess response to treatment.

MRI data acquisition

3 T Siemens Trio Tim scanner (32 channel head coil) at the Murdoch Children's Research Institute in Melbourne, Australia, was used to acquire high-resolution structural T1 Magnetisation-Prepared Rapid Gradient-Echo (MPRAGE)³² scans for each subject. Image acquisition parameters at every time point were as follows: 192 sagittal slices with a nominal 1 mm³ voxel size, 256 mm × 232 mm field-of-view and a matrix size of 256 × 192 pixel resolution, 2000 ms repetition time and 2.24 ms echo time. Structural images of 25 patients were sampled at twice the resolution resulting in a matrix size of 512 × 384 pixels and an in-plane resolution of 0.5 mm × 0.5 mm.

Voxel-based morphometry (pre-processing)

Pre-processing and post-processing for baseline and longitudinal comparisons were carried out in the VBM8 toolbox implemented in Statistical Parametric Mapping (SPM8; <http://www.fil.ion.ucl.ac.uk/spm/software/spm8/>) running in Matlab v.8.1 (MathWorks, Matick, MA, USA). Structural images were routinely inspected for artifacts and gross abnormalities. For baseline comparison voxel-wise analyses of brain gray matter volume and white matter volume differences were conducted using the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL³³). Briefly, each participant's T1-weighted anatomical scan was segmented into distinct tissue compartments and spatially normalised. A study-specific template was generated by normalising each participant's segmented grey or white matter image to a common space. Native-space grey or white matter images were then spatially normalised to this template. Modulation (nonlinear only) normalisation was used to preserve the amount of grey and white matter. The resulting modulated and spatially normalised segments were then smoothed with a 6.0 mm full width at half maximum spatial smoothing kernel in order to minimise anatomical residuals from registration. Grey and white matter segments

Figure 1. Z-score statistical map of reduced grey matter (left inset) and white matter (right inset) volume in first-episode mania patients ($N=39$) when compared with healthy control subjects ($N=30$) at baseline. Right hemisphere is shown on the right. Numbers represent MNI coordinates in each corresponding plane. Results are threshold-free cluster-enhancement-corrected for multiple comparison ($P_{TFCE} < 0.01$). See Table 2 for more information. MNI, Montreal Neurological Institute.

were checked for segmentation and normalisation artifacts. Intracranial volume was calculated from the raw anatomical images in the subject's native space as the total volume of grey matter, white matter and cerebrospinal fluid.

For longitudinal comparison, the VBM8 longitudinal pipeline was used. Briefly, for each subject, after follow-up images were initially realigned to baseline, a mean image was created and used as a reference image to which baseline and longitudinal images were realigned again. The realigned images at each time point were then corrected for signal inhomogeneity (bias correction) and segmented. Spatial normalisation using DARTEL was applied to the reference image, after which normalisation parameters were applied to the realigned and bias-corrected segments.

Statistical analyses

Baseline differences in grey and white matter volume between FEM patients (collapsed across treatment groups) and control subjects were tested using the General Linear Model as implemented in the FSL feature Randomise (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Randomise>). All results were corrected for type I error with a nonparametric threshold-free cluster enhancement procedure employing 1000 permutations.³⁴ Age and gender were included as covariates of no interest. Results were considered significant if they passed a threshold $P < 0.01$. The results were then saved to mask treatment $\times$ time interaction results, thus ensuring that treatment effects were investigated in brain regions of primary pathophysiological importance to BD.

To examine changes in grey and white matter volume in response to treatment over time, preprocessed whole-brain grey and white matter segments were entered into separate flexible factorial models with group (control, quetiapine and lithium) and time (baseline, 3 months and 12 months) as factors and age, gender, DSM-IV-TR diagnosis (see Supplementary Table 1 for more information) and psychotropic medication as covariates of interest. In this analysis the effect of lithium versus quetiapine treatment on longitudinal changes in baseline differences in grey and white matter (treatment $\times$ time interaction) was the outcome measure. Group $\times$ time interactions were modelled using an F-test masked with the between-group difference results generated at baseline. Interaction results were corrected for multiple comparisons using small-volume correction as implemented in SPM8 with the between-group difference results mask generated at baseline as the volume of interest. Results that survived a threshold of $P < 0.01$ were considered significant. A group $\times$ time interaction plot was generated by extracting the first eigenvariate (weighted averages) of white matter volume estimates from clusters that survived correction for multiple comparisons (Figure 1). Three months' follow-up data were compared separately for treatment groups exclusive of control data. Three months' follow-up data for control subjects were estimated by linear interpolation of baseline and 12 months data points and included for presentation purposes only.

RESULTS

Of the 61 recruited subjects, 11 in the quetiapine treatment group and 9 in the lithium treatment group were excluded at or before

randomisation took place for the following reasons: relapse at baseline or before commencement of monotherapy ($n=5$); self-ceasing of all medications ($n=3$); non-stability on monotherapy ($n=2$); preference for the non-randomized medication ($n=3$); clinician withdrawal due to side effects ($n=2$); and treatment disengagement ($n=4$). Twenty-one patients were allocated to quetiapine treatment and 20 subjects were allocated to lithium. Two additional subjects were excluded at baseline; one subject because of never being on monotherapy and one subject because of non-compliance to randomized medication, rendering a final sample of 19 subjects in the quetiapine group and 20 subjects in the lithium group. Three patients in the quetiapine group and four in the lithium group discontinued after their baseline participation.

Treatment groups were matched for age, gender, handedness and intelligence quotient, but only matched for age and handedness with the control group (Table 1). Treatment groups (lithium and quetiapine) clinical scores did not differ across all clinical scales at baseline, indicating that stabilisation was successful (Table 1).

FEM patients (collapsed across treatment groups) demonstrated reduced regional grey and white matter volume compared with control subjects at baseline ($P < 0.01$ corrected; Figure 1 and Table 2). Specifically, patients showed reduced grey matter volume in the orbitofrontal cortex, anterior cingulate cortex and the inferior frontal gyrus, as well as in the cerebellum (Figure 1 and Table 2). In addition, patients had reduced internal capsule white matter volume bilaterally (Figure 1 and Table 2). These findings clarify brain areas affected in participants stabilized in the aftermath of a FEM, and before monotherapy was commenced.

Longitudinally, there was a significant treatment $\times$ time effect only in the white matter of the left internal capsule ($F_{2,112} = 10.44$, $P < 0.01$; Table 2 and Figure 2). To further assess whether the treatment effect exceeds the test-retest variability in control subjects, we assessed treatment $\times$ time interaction for each of the treatment group separately with the control group. We found no group $\times$ time interaction effect for the lithium group when compared with healthy control subjects and only in the quetiapine group ($F = 12.32$, $P < 0.01$ corrected). *Post hoc* testing showed that lithium was more effective than quetiapine in slowing the progression of white matter volume reduction as suggested by the difference score in white matter estimates between baseline and 12 months only ($t_{1,24} = 3.76$, $P < 0.01$; Figure 2) but not after 3 months ($t_{1,27} = 1.3$, $P = 0.21$). There were no other reductions or increases in grey or white matter volumes over time across any of the groups.

DISCUSSION

To the best of our knowledge, this is the first longitudinal structural neuroimaging study to characterize the neuroprotective effects of lithium and quetiapine in participants following a FEM. Compared with healthy controls, FEM patients demonstrated reduction in brain volume in a number of previously identified areas,^{12,35,36} including the orbitofrontal cortex, anterior cingulate cortex, inferior frontal gyrus and cerebellum at baseline. Volumetric reductions in white matter were restricted to the internal capsule bilaterally. Furthermore, we assessed differences in the effect of treatment across three time points, which has not previously been done. We found a significant effect of treatment on white matter, with the lithium group showing an attenuated reduction of white matter volume over time compared with the quetiapine group at 12 months of follow-up.

At baseline, we identified between-group differences confined to structures widely implicated in BD.³⁷ We did not identify any regional changes in disease-specific grey matter across groups over time, and this absence of change is corroborated by another longitudinal study of FEM patients with BD.³⁸ However, there are

Table 1. Demographic and clinical characteristics of FEM patients and healthy control subjects

Demographics	Control N = 30		Quetiapine (N = 19)		Lithium (N = 20)		Statistics	
	N	%	N	%	N	%	χ^2	P
Gender								
Male	12	40	14	70	16	84	9.87	0.007
Female	18	60	5	30	4	16		
Handedness ^a								
Right-handed	26	93	15	83	19	95	3.64	0.162
Left-handed	2	7	3	17	0	0		
Age	Mean	s.d.	Mean	s.d.	Mean	s.d.	F	
Premorbid IQ (WTAR)	21.40 105.43	2.46 10.82	21.47 92.89	2.14 13.80	21.45 96.71	2.31 13.89	0.145 11.37	0.88 0.001
Baseline clinical scores ^b (total)	Control		Quetiapine		Lithium		Statistics	
	Mean	s.d.	Mean	s.d.	Mean	s.d.	Mann-Whitney Z	P
YMRS	—	—	1.86	2.21	2.85	4.4	−0.074	0.941
MADRS	—	—	7.05	8.63	7.05	9.09	−0.667	0.505
CGI-BP (Severity of overall bipolar)	—	—	1.89	1.52	2.10	1.48	−0.677	0.498
CGI-BP (Severity of mania)	—	—	1.00	0.00	1.20	0.70	−1.396	0.163
CGI-BP (Severity of depression)	—	—	2.00	1.49	2.10	1.71	−0.047	0.962
BPRS	—	—	32.47	8.42	33.80	10.19	−0.297	0.767

Abbreviations: BPRS, Brief Psychiatric Rating Scale; CGI-BP, Clinical Global Impressions scale for use in bipolar disorder; FEM, first-episode mania; IQ, intelligence quotient; MADRS, Montgomery Asperger Depressive Rating Scale; WTAR, Wechsler Test of Adult Reading (UK-scaled score); YMRS, Young Mania Rating Scale. ^aData for two subjects in the control group and one subject in the quetiapine and the lithium group were missing. ^bFollow-up data for four and seven subjects were missing from the quetiapine and lithium group, respectively.

Table 2. Brain regions demonstrating baseline differences as well as group × time interaction effect in grey and white matter volume between first-episode mania patients and control subjects

Baseline comparison	Hemisphere	Peak MNI coordinates (x,y,z)	Cluster size voxels (mm ³)	z-score
<i>Grey Matter</i>				
Orbitofrontal cortex/gyrus rectus	Right	−3, 38, −27	170 (574)	4.56
Cerebellum	Left	−30, −66, −21	1190 (4016)	5.12
Cerebellum	Right	39, −63, −22	1755 (5923)	5.07
<i>White matter</i>				
Internal capsule	Right	20, −18, 2	336 (1134)	5.29
Internal capsule	Left	−22, −19, −6	171 (577)	5.37
<i>Group × time interaction (white matter)</i>				
Internal capsule	Left	−22, −19, −8	82 (277)	3.64

Abbreviation: MNI, Montreal Neurological Institute. Results are corrected for multiple comparison ($P < 0.01$).

structural neuroimaging findings that suggest a progressive grey matter loss in the prefrontal cortex and anterior cingulate cortex in BD.³⁹ The absence of grey matter alterations over time may be a result of a neuroprotective effect of medications or due to common neuropathology limited to psychotic illnesses that differentiates after first episode of mania.^{38,40} This notion is supported by finding that progressive loss of grey matter in both the cingulate cortex and the cerebellum have been shown to be specific to subjects who later on developed psychosis.⁴¹

The superiority of lithium on white, but not grey, matter outcomes contrasts with previous findings.^{12,35} Demonstrating an increased volume in the anterior cingulate cortex,¹² hippocampus

and amygdala⁴² was associated with lithium treatment in BD patients. Nonetheless, our finding of no change in grey matter over time is in agreement with a number of other studies that found either no change in grey matter volume⁴³ or more extensive changes in white matter volume only.^{38,40} The discrepancy in these findings can be attributed to the relatively lower incidence of multiple episodes and hence abnormalities severity in this sample compared with other studies¹⁵ and the relative age of participants.⁴⁴

Although reduced white matter in the internal capsule volume was detected bilaterally at baseline, we detected a treatment effect only in the left hemisphere. This result may suggest that left

Figure 2. Time plot of significant changes in white matter volume over time in the left internal capsule (inset). Asterisk: significant between treatment group differences corrected ($P_{SMV} < 0.01$); error bars represent s.d. See Results section, Table 2 and Supplementary Materials for more information.

white matter volume is more susceptible to illness processes in FEM patients in this brain region. This notion is in agreement with previous findings, showing a longitudinal reduction in white matter volume to be more affected in the left hemisphere (6.5%) in bipolar patients when compared with baseline.⁴⁵ Furthermore, structural imaging studies investigating aspects of water diffusion in white matter fibre tracts have shown reduced fractional anisotropy in the left internal capsule only⁴⁶ and loss of the normal left-sided symmetry in the posterior limb of the internal capsule,⁴⁷ suggesting specific microstructural abnormality to the left hemisphere.

The duration of lithium treatment in this study is worth considering as it points to an effective cessation of white matter loss during the first 3 months and a subsequent normalisation of this effect to similar rate to that expected in control subjects (Figure 2). Previous studies demonstrated that among people with BD those with a greater duration of treatment with lithium manifested better adjusted white matter⁴⁸ as well as grey matter integrity.⁴⁹ In addition, there are preliminary reports of associations between white matter hyperintensities and better lithium response.⁵⁰ These findings strongly suggest that lithium has a role in myelin physiology. In a crush injury model, for example, lithium is shown to enhance the re-myelination of peripheral nerves.⁵¹ An operative pathway whereby lithium acts on white matter seems to be via glycogen synthase kinase 3- β .⁵² The mechanism involves regulation of the genes for myelin basic protein and proteolipid protein expression in mouse oligodendrocytes.⁵³

The results of this study do not support a neuroprotective role for quetiapine nor do they support a neurotoxic effect. This is clearly demonstrated by the fact that treatment groups did not differ on measures of both grey and white matter at baseline or in grey matter longitudinally. Rather, quetiapine seems to take much longer to exert an effect on white matter, suggesting perhaps a slower and less potent effect than lithium. Despite being a multisite study conducted over 5 years, the sample size of this study was limited. This is driven by the low incidence of FEM, together with the requirement to have been treated and stabilized on a combination of lithium and quetiapine, and to then agree to randomisation, be happy with the randomized agent and the trial assessments. As expected, there was a group of individuals who did not complete the trial, decreasing power at the final time point.

White matter neuroimaging metrics that reflect axonal structure, such as fractional anisotropy, and the mean and radial

diffusivity are altered in people with BD compared with controls.⁵⁴ Alterations in white matter microarchitecture have also been shown to be associated with poorer treatment response.⁵⁵ This suggests that there is a process of disturbed myelination in the disorder that is seemingly not associated with axonal loss.⁵⁶ Such changes can only be assessed with diffusion imaging that may prove more sensitive to axonal pathology than voxel-based morphometry analysis.

That most patients had psychotic symptoms at baseline means that these data cannot be extrapolated to non-psychotic individuals. The cohort included individuals with bipolar and schizoaffective disorder, although only a small number of participants had the latter diagnosis. Data regarding quetiapine cannot be extrapolated to other antipsychotics. To make the trial feasible, concomitant medications were allowed, and their role cannot be excluded. Dropout rates of around a third are not unexpected in a first-episode population, and the results need to be interpreted cognizant of this characteristic. Similarly, there was an imbalance between patients and controls regarding intelligence quotient and gender, which is a limitation. High rates of substance use in the cohort may have influenced the results, although both treatment groups were matched for subjects with substance/alcohol abuse and hence the results are not likely to be attributed to their effect. Because substance abuse is very common in this population, it was allowed to enhance generalisation. The randomized design, the two post-baseline scans using a single scanner and the 1-year follow-up are strengths of the design.

In summary, the data support the role of lithium in preventing white matter changes after a first episode of mania. In addition, given the progressive nature of the disorder, and the lack of data showing that established cognitive or imaging changes could be reversed, these data support the continuing use of lithium from the earliest stages of the disorder, pragmatically translated as the first episode. They thus challenge earlier guidelines, suggesting that one might wait for the passage of several episodes before commencing lithium.^{57–61}

CONFLICT OF INTEREST

MB has received Grant/Research Support from Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth and served as a consultant to Astra Zeneca, Bioadvantex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and Servier. PM has received investigator-initiated research grants from Astra Zeneca, Janssen Cilag, Eli Lilly and BMS. He has received honoraria for educational events from Janssen Cilag, Eli Lilly, BMS, Astra Zeneca, Pfizer and Lundbeck. CP has participated on Advisory Boards for Janssen Cilag, Astra Zeneca, Lundbeck and Servier, and has received honoraria for talks presented at educational meetings organised by Astra Zeneca, Janssen Cilag, Eli Lilly, Pfizer, Lundbeck and Shire. CM has received honoraria for talks at meetings organised by Astra Zeneca, Janssen Cilag, Sanofi Synthelabo and Eli Lilly, and has been on a consultation panel for Eli Lilly. BL received funding from Svenska Läkaresällskapet (The Swedish Society of Medicine, SLS-403101), and Forskningsrådet, Karolinska Institutet, Stockholm County Council, Sweden. The remaining authors declare no conflicts of interest.

ACKNOWLEDGMENTS

This study was supported by an unrestricted grant from Astra Zeneca. MB was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship 1059660. CS was supported by a NHMRC Career Development Fellowship 1061998. CSP was supported by a NHMRC Senior Principal Research Fellowship (ID: 628386). AF was supported by the Australian Research Council (ID: FT130100589). KA was supported by a Ronald Philip Griffiths Fellowship, The University of Melbourne. PK was supported by the Swiss National Science Foundation (SNSF) and the Swiss Society for Medicine and Biology Scholarships (ID:148384). PM was supported by a NHMRC SPRF. MY was supported by a National Health and Medical Research Council of Australia Fellowship (ID:APP1021973).

REFERENCES

- Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. *Br J Psychiatry* 1998; **172**: 23–28.
- Kraepelin E. *Manic-Depressive Insanity and Paranoia*. Arno Press: New York, NY, USA, 1976, pp xv 280.
- Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci Biobehav Rev* 2011; **35**: 804–817.
- Fries GR, Pfaffenseller B, Stertz L, Paz AV, Dargel AA, Kunz M et al. Staging and neuroprogression in bipolar disorder. *Curr Psychiatr Rep* 2012; **14**: 667–675.
- Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. *Clin Psychiatry* 2005; **66**: 693–704.
- Matza LS, Rajagopalan KS, Thompson CL, de Lissoyov G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. *J Clin Psychiatry* 2005; **66**: 1432–1440.
- Reinares M, Colom F, Rosa AR, Bonnin CM, Franco C, Sole B et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. *J Affect Disord* 2010; **123**: 81–86.
- Rosa AR, Gonzalez-Ortega I, Gonzalez-Pinto A, Echeburua E, Comes M, Martinez-Aran A et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. *Acta Psychiatr Scand* 2012; **125**: 335–341.
- Lopez-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder. *Biol Psychiatry* 2002; **52**: 93–100.
- Sassi RB, Brambilla P, Hatch JP, Nicoletti MA, Mallinger AG, Frank E et al. Reduced left anterior cingulate volumes in untreated bipolar patients. *Biol Psychiatry* 2004; **56**: 467–475.
- Ekman CJ, Lind J, Ryden E, Ingvar M, Landen M. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. *Acta Psychiatr Scand* 2010; **122**: 507–515.
- Bora E, Fornito A, Yucel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. *Biol Psychiatry* 2010; **67**: 1097–1105.
- Javadpour A, Malhi GS, Ivanovski B, Chen X, Wen W, Sachdev P. Hippocampal volumes in adults with bipolar disorder. *J Neuropsychiatr Clin Neurosci* 2010; **22**: 55–62.
- Moorhead TW, McKirdy J, Sussmann JE, Hall J, Lawrie SM, Johnstone EC et al. Progressive gray matter loss in patients with bipolar disorder. *Biol Psychiatry* 2007; **62**: 894–900.
- Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. *Am J Psychiatry* 2002; **159**: 1841–1847.
- Daglas R, Yucel M, Cotton S, Allott K, Hetrick S, Berk M. Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. *Int J Bipolar Disord* 2015; **3**: 9.
- Arango C, Rapado-Castro M, Reig S, Castro-Fornieles J, Gonzalez-Pinto A, Otero S et al. Progressive brain changes in children and adolescents with first-episode psychosis. *Arch Gen Psychiatry* 2012; **69**: 16–26.
- de Castro-Mangano P, Mechelli A, Soutullo C, Gimenez-Amaya J, Ortuno F, McGuire P. Longitudinal changes in brain structure following the first episode of psychosis. *Psychiatr Res* 2011; **191**: 166–173.
- Bora E, Pantelis C. Meta-analysis of cognitive impairment in first-episode bipolar disorder: comparison with first-episode schizophrenia and healthy controls. *Schizophr Bull* 2015; **41**: 1095–1104.
- Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. *Neuropsychopharmacology* 2010; **35**: 1743–1750.
- Nakamura M, Salisbury DF, Hirayasu Y, Bouix S, Pohl KM, Yoshida T et al. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. *Biol Psychiatry* 2007; **62**: 773–783.
- Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhde TW et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. *J Clin Psychiatry* 2009; **70**: 699–705.
- Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. *Bipolar Disord* 2012; **14**: 375–410.
- Boonstra G, van Haren NE, Schnack HG, Cahn W, Burger H, Boersma M et al. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. *J Clin Psychopharmacol* 2011; **31**: 146–153.
- Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. *Psychol Med* 2009; **39**: 1763–1777.
- Yang C, Wu S, Lu W, Bai Y, Gao H. Brain differences in first-episode schizophrenia treated with quetiapine: a deformation-based morphometric study. *Psychopharmacology* 2015; **232**: 369–377.
- Ebdurp BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, Lublin H et al. Progressive striatal and hippocampal volume loss in initially antipsychotic-naïve, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. *Int J Neuropsychopharmacol* 2011; **14**: 69–82.
- First MB, Spitzer Robert L, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York, NY, USA, 2002.
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; **134**: 382–389.
- Ventura JLD, Nuechterlein KH, Lieberman RP, Green M, Shaner A. Brief Psychiatric Ratings Scale (BPRS) Expanded Version (4.0) scales, anchor points and administration manual. *Int J Methods Psychiatr Res* 1993; **3**: 227–243.
- Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. *Psychiatr Res* 1997; **73**: 159–171.
- Mugler JP 3rd, Brookeman JR. Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magn Reson Med* 1990; **15**: 152–157.
- Ashburner J. A fast diffeomorphic image registration algorithm. *NeuroImage* 2007; **38**: 95–113.
- Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *NeuroImage* 2009; **44**: 83–98.
- Bora E, Pantelis C. Structural trait markers of bipolar disorder: disruption of white matter integrity and localized gray matter abnormalities in anterior fronto-limbic regions. *Biol Psychiatry* 2011; **69**: 299–300.
- Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. *Schizophr Res* 2010; **117**: 1–12.
- Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L et al. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. *Biol Psychiatry* 2013; **73**: 144–152.
- Watson DR, Anderson JM, Bai F, Barrett SL, McGinnity TM, Mulholland CC et al. A voxel based morphometry study investigating brain structural changes in first episode psychosis. *Behav Brain Res* 2012; **227**: 91–99.
- Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. *Neurosci Biobehav Rev* 2013; **37**: 418–435.
- De Peri L, Crescini A, Deste G, Fusar-Poli P, Sacchetti E, Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. *Curr Pharm Design* 2012; **18**: 486–494.
- Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ et al. Neuro-anatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet* 2003; **361**: 281–288.
- Hallahan B, Newell J, Soares JC, Brambilla P, Strakowski SM, Fleck DE et al. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. *Biol Psychiatry* 2011; **69**: 326–335.
- Amann BL, Canales-Rodriguez EJ, Madre M, Radua J, Monte G, Alonso-Lana S et al. Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder. *Acta Psychiatr Scand* 2015; **133**: 23–33.
- Kalmar JH, Wang F, Spencer L, Edmiston E, Lacadie CM, Martin A et al. Preliminary evidence for progressive prefrontal abnormalities in adolescents and young adults with bipolar disorder. *J Int Neuropsychol Soc* 2009; **15**: 476–481.
- Dickey CC, Salisbury DF, Nagy AI, Hirayasu Y, Lee CU, McCarley RW et al. Follow-up MRI study of prefrontal volumes in first-episode psychotic patients. *Schizophr Res* 2004; **71**: 349–351.
- Chaddock CA, Barker GJ, Marshall N, Schulze K, Hall MH, Fern A et al. White matter microstructural impairments and genetic liability to familial bipolar I disorder. *Br J Psychiatry* 2009; **194**: 527–534.
- Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, LiCalzi EM et al. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. *Biol Psychiatry* 2005; **57**: 733–742.
- Gildengers AG, Butters MA, Aizenstein HJ, Marron MM, Emanuel J, Anderson SJ et al. Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder. *Bipolar disorders* 2015; **17**: 248–256.
- Germana C, Kempton MJ, Sarnicola A, Christodoulou T, Haldane M, Hadjulis M et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. *Acta Psychiatr Scand* 2010; **122**: 481–487.
- Kato T, Fujii K, Kamiya A, Kato N. White matter hyperintensity detected by magnetic resonance imaging and lithium response in bipolar disorder: a preliminary observation. *Psychiatr Clin Neurosci* 2000; **54**: 117–120.

- 51 Makoukji J, Belle M, Meffre D, Stassart R, Grenier J, Shackleford G *et al*. Lithium enhances remyelination of peripheral nerves. *Proc Natl Acad Sci USA* 2012; **109**: 3973–3978.
- 52 Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C *et al*. Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. *Neuropsychopharmacology* 2013; **38**: 313–327.
- 53 Meffre D, Massaad C, Grenier J. Lithium chloride stimulates PLP and MBP expression in oligodendrocytes via Wnt/beta-catenin and Akt/CREB pathways. *Neuroscience* 2015; **284**: 962–971.
- 54 Bauer IE, Ouyang A, Mwangi B, Sanches M, Zunta-Soares GB, Keefe RS *et al*. Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study. *J Psychiatr Res* 2015; **62**: 115–122.
- 55 Bollettini I, Poletti S, Locatelli C, Vai B, Smeraldi E, Colombo C *et al*. Disruption of white matter integrity marks poor antidepressant response in bipolar disorder. *J Affect Disord* 2015; **174**: 233–240.
- 56 Benedetti F, Bollettini I. Recent findings on the role of white matter pathology in bipolar disorder. *Har Rev Psychiatry* 2014; **22**: 338–341.
- 57 Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ, Disorders WtFoTGfB. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. *World J Biol Psychiatry* 2004; **5**: 120–135.
- 58 Yamada S, Takahashi S, Ukai S, Tsuji T, Iwatani J, Tsuda K *et al*. Microstructural abnormalities in anterior callosal fibers and their relationship with cognitive function in major depressive disorder and bipolar disorder: a tract-specific analysis study. *J Affect Disord* 2015; **174**: 542–548.
- 59 Katagiri N, Pantelis C, Nemoto T, Zalesky A, Hori M, Shimoji K *et al*. A longitudinal study investigating sub-threshold symptoms and white matter changes in individuals with an 'at risk mental state' (ARMS). *Schizophr Res* 2015; **162**: 7–13.
- 60 Roybal DJ, Barnea-Goraly N, Kelley R, Bararpour L, Howe ME, Reiss AL *et al*. Widespread white matter tract aberrations in youth with familial risk for bipolar disorder. *Psychiatr Res* 2015; **232**: 184–192.
- 61 Monkul ES, Matsuo K, Nicoletti MA, Dierschke N, Hatch JP, Dalwani M *et al*. Pre-frontal gray matter increases in healthy individuals after lithium treatment: a voxel-based morphometry study. *Neurosci Lett* 2007; **429**: 7–11.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017

Supplementary Information accompanies the paper on the Translational Psychiatry website (<http://www.nature.com/tp>)